A retrospective chart review will be conducted to identify patients receiving breast reconstruction and simultaneous breast neurotization. Their reconstructed breasts will be included as study group. Patients receiving breast reconstruction without neurotization will be included as negative control group. Their contralateral normal breasts in the study and the negative control group will be included as positive control. Patients' demographic data, their breast cancer treatment parameters, such as the staging, previous radiotherapy history, postmastectomy radiotherapy, neoadjuvant and adjuvant chemotherapy will be included. The reconstruction results will be evaluated as well.

Statistics Data will be analyzed using graphing and statistical analysis software. Independent t test will be applied to calculate continuous variables in demographic values, while Chi-square will be applied to calculate categorical variables such as postoperative complications. A probability of less than 0.05 will be considered significant.

Potential risks: No

Confidentiality:

All the patient identifiable information, which includes name, chart number and birthday, involved in the study will be strictly confidential.

Inclusion Criteria:

• patients who received breast reconstruction and neurotization from July 2019 to August 2022 from a single breast reconstruction surgeon.
• patients who received breast reconstruction without neurotization were included as the non-neurotized group.

Exclusion Criteria:

• patients unable to complete the follow-up were excluded from the study

patients who received breast reconstruction and neurotization from July 2019 to August 2022 from a single breast reconstruction surgeon.